We are analyzing https://link.springer.com/article/10.1007/s00592-014-0691-y.

Title:
Cancer and bone fractures in observational follow-up of the RECORD study | Acta Diabetologica
Description:
The RECORD study evaluated the effects of rosiglitazone on cardiovascular outcomes. A 4-year observational follow-up was added to the study to monitor the occurrence of cancer and bone fractures. We present the cancer and bone fracture data aggregated across the main study and its observational follow-up. RECORD was a multicentre, open-label trial in people with type 2 diabetes on metformin or sulfonylurea monotherapy randomly assigned to addition of rosiglitazone (n = 2,220) or to a combination of metformin and sulfonylurea (n = 2,227). At the end of the main study, patients stopped study drug and were invited to enter the observational follow-up during which glucose-lowering treatment was selected by the patient’s physician. Serious adverse events of cancer and serious and non-serious events of bone fracture were recorded. The study is registered with ClinicalTrials.gov, number NCT00379769. Of the 4,447 patients comprising the intent-to-treat population, 2,546 entered the observational follow-up (1,288 rosiglitazone, 1,258 metformin/sulfonylurea) and added 9,336 patient-years experience to the main RECORD study, making an aggregate of 33,744 patient-years. Based on the totality of follow-up, malignancies were reported in 179 of 2,220 patients (8.1 %) in the group originally randomised to rosiglitazone and in 195 of 2,227 patients (8.8 %) in the group allocated metformin/sulfonylurea [relative risk, RR, 0.92 (95 % CI 0.76–1.12)]. More patients reported bone fractures in the rosiglitazone group (238, 10.7 %) than in the metformin/sulfonylurea control [151, 6.8 %; RR 1.58 (1.30–1.92)]. For women, the corresponding figures were rosiglitazone 156 (14.5 %), metformin/sulfonylurea 91 (8.5 %), RR 1.71 (1.34–2.18), and for men, the corresponding figures were rosiglitazone 82 (7.2 %), metformin/sulfonylurea 60 (5.2 %), RR 1.37 (0.99–1.90). Potentially high-morbidity fractures (hip, pelvis, femur, and spine) occurred in the same number of patients (31, 1.4 %) in the two treatment groups. We conclude that data from a 4-year observational follow-up, combined with the main RECORD study data, do not suggest an increased risk of cancer in patients randomised to rosiglitazone combination use compared with those randomised to metformin/sulfonylurea. Consistent with the main study, rosiglitazone is associated with an increased risk of peripheral bone fracture in women, and probably in men, but the combined data do not suggest an increase in potentially high-morbidity (hip, pelvis, femur, and spine) fractures.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Insurance
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

study, pubmed, cancer, article, google, scholar, rosiglitazone, cas, patients, diabetes, record, bone, data, observational, followup, home, jones, risk, main, access, fractures, type, metformin, metforminsulfonylurea, randomised, privacy, cookies, content, curtis, cardiovascular, fracture, trial, thiazolidinediones, information, publish, research, search, acta, nigel, evaluated, outcomes, events, group, clinical, med, colon, glaxosmithkline, consent, log, journal,

Topics {✒️}

gov/ohrms/dockets/ac/05/slides/2005-4169s2_02_02-fda-elhage month download article/chapter c57bl/6 j-apcmin/+ mice c57bl/6j-apcmin/+ mice oral glucose-lowering drugs real-world cohort study peripheral bone fracture potentially high-morbidity fractures open-label trial full article pdf glucose-lowering products privacy choices/manage cookies kahn se related subjects bone fracture potentially high-morbidity her2 + breast cancer cardiovascular disease glucose-lowering treatment analysis cancer risk european economic area de bruyn arv thiazolidinedione pparγ agonists yeung s-cj affiliated receive funding ethics review committees stockley park west high-risk patients adopt study group conditions privacy policy group originally randomised institutional review boards randomised controlled trial ppargamma-independent pathways randomised controlled adopt accepting optional cookies bone fractures macro-vascular events randomized clinical trials cell cycle proteins main record study 4-year observational follow metformin/sulfonylurea control [151 thiazolidinediones regulate expression record study evaluated article log journal finder publish ppar res article jones instant access

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cancer and bone fractures in observational follow-up of the RECORD study
         description: The RECORD study evaluated the effects of rosiglitazone on cardiovascular outcomes. A 4-year observational follow-up was added to the study to monitor the occurrence of cancer and bone fractures. We present the cancer and bone fracture data aggregated across the main study and its observational follow-up. RECORD was a multicentre, open-label trial in people with type 2 diabetes on metformin or sulfonylurea monotherapy randomly assigned to addition of rosiglitazone (n = 2,220) or to a combination of metformin and sulfonylurea (n = 2,227). At the end of the main study, patients stopped study drug and were invited to enter the observational follow-up during which glucose-lowering treatment was selected by the patient’s physician. Serious adverse events of cancer and serious and non-serious events of bone fracture were recorded. The study is registered with ClinicalTrials.gov, number NCT00379769. Of the 4,447 patients comprising the intent-to-treat population, 2,546 entered the observational follow-up (1,288 rosiglitazone, 1,258 metformin/sulfonylurea) and added 9,336 patient-years experience to the main RECORD study, making an aggregate of 33,744 patient-years. Based on the totality of follow-up, malignancies were reported in 179 of 2,220 patients (8.1 %) in the group originally randomised to rosiglitazone and in 195 of 2,227 patients (8.8 %) in the group allocated metformin/sulfonylurea [relative risk, RR, 0.92 (95 % CI 0.76–1.12)]. More patients reported bone fractures in the rosiglitazone group (238, 10.7 %) than in the metformin/sulfonylurea control [151, 6.8 %; RR 1.58 (1.30–1.92)]. For women, the corresponding figures were rosiglitazone 156 (14.5 %), metformin/sulfonylurea 91 (8.5 %), RR 1.71 (1.34–2.18), and for men, the corresponding figures were rosiglitazone 82 (7.2 %), metformin/sulfonylurea 60 (5.2 %), RR 1.37 (0.99–1.90). Potentially high-morbidity fractures (hip, pelvis, femur, and spine) occurred in the same number of patients (31, 1.4 %) in the two treatment groups. We conclude that data from a 4-year observational follow-up, combined with the main RECORD study data, do not suggest an increased risk of cancer in patients randomised to rosiglitazone combination use compared with those randomised to metformin/sulfonylurea. Consistent with the main study, rosiglitazone is associated with an increased risk of peripheral bone fracture in women, and probably in men, but the combined data do not suggest an increase in potentially high-morbidity (hip, pelvis, femur, and spine) fractures.
         datePublished:2014-12-19T00:00:00Z
         dateModified:2014-12-19T00:00:00Z
         pageStart:539
         pageEnd:546
         sameAs:https://doi.org/10.1007/s00592-014-0691-y
         keywords:
            Cancer
            Fracture
            Rosiglitazone
            RECORD
            Internal Medicine
            Diabetes
            Metabolic Diseases
         image:
         isPartOf:
            name:Acta Diabetologica
            issn:
               1432-5233
               0940-5429
            volumeNumber:52
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Milan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Nigel P. Jones
               affiliation:
                     name:GlaxoSmithKline
                     address:
                        name:GlaxoSmithKline, Uxbridge, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Paula S. Curtis
               affiliation:
                     name:GlaxoSmithKline
                     address:
                        name:GlaxoSmithKline, Uxbridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Philip D. Home
               affiliation:
                     name:Newcastle University
                     address:
                        name:Newcastle University, Newcastle upon Tyne, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cancer and bone fractures in observational follow-up of the RECORD study
      description: The RECORD study evaluated the effects of rosiglitazone on cardiovascular outcomes. A 4-year observational follow-up was added to the study to monitor the occurrence of cancer and bone fractures. We present the cancer and bone fracture data aggregated across the main study and its observational follow-up. RECORD was a multicentre, open-label trial in people with type 2 diabetes on metformin or sulfonylurea monotherapy randomly assigned to addition of rosiglitazone (n = 2,220) or to a combination of metformin and sulfonylurea (n = 2,227). At the end of the main study, patients stopped study drug and were invited to enter the observational follow-up during which glucose-lowering treatment was selected by the patient’s physician. Serious adverse events of cancer and serious and non-serious events of bone fracture were recorded. The study is registered with ClinicalTrials.gov, number NCT00379769. Of the 4,447 patients comprising the intent-to-treat population, 2,546 entered the observational follow-up (1,288 rosiglitazone, 1,258 metformin/sulfonylurea) and added 9,336 patient-years experience to the main RECORD study, making an aggregate of 33,744 patient-years. Based on the totality of follow-up, malignancies were reported in 179 of 2,220 patients (8.1 %) in the group originally randomised to rosiglitazone and in 195 of 2,227 patients (8.8 %) in the group allocated metformin/sulfonylurea [relative risk, RR, 0.92 (95 % CI 0.76–1.12)]. More patients reported bone fractures in the rosiglitazone group (238, 10.7 %) than in the metformin/sulfonylurea control [151, 6.8 %; RR 1.58 (1.30–1.92)]. For women, the corresponding figures were rosiglitazone 156 (14.5 %), metformin/sulfonylurea 91 (8.5 %), RR 1.71 (1.34–2.18), and for men, the corresponding figures were rosiglitazone 82 (7.2 %), metformin/sulfonylurea 60 (5.2 %), RR 1.37 (0.99–1.90). Potentially high-morbidity fractures (hip, pelvis, femur, and spine) occurred in the same number of patients (31, 1.4 %) in the two treatment groups. We conclude that data from a 4-year observational follow-up, combined with the main RECORD study data, do not suggest an increased risk of cancer in patients randomised to rosiglitazone combination use compared with those randomised to metformin/sulfonylurea. Consistent with the main study, rosiglitazone is associated with an increased risk of peripheral bone fracture in women, and probably in men, but the combined data do not suggest an increase in potentially high-morbidity (hip, pelvis, femur, and spine) fractures.
      datePublished:2014-12-19T00:00:00Z
      dateModified:2014-12-19T00:00:00Z
      pageStart:539
      pageEnd:546
      sameAs:https://doi.org/10.1007/s00592-014-0691-y
      keywords:
         Cancer
         Fracture
         Rosiglitazone
         RECORD
         Internal Medicine
         Diabetes
         Metabolic Diseases
      image:
      isPartOf:
         name:Acta Diabetologica
         issn:
            1432-5233
            0940-5429
         volumeNumber:52
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Milan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Nigel P. Jones
            affiliation:
                  name:GlaxoSmithKline
                  address:
                     name:GlaxoSmithKline, Uxbridge, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Paula S. Curtis
            affiliation:
                  name:GlaxoSmithKline
                  address:
                     name:GlaxoSmithKline, Uxbridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Philip D. Home
            affiliation:
                  name:Newcastle University
                  address:
                     name:Newcastle University, Newcastle upon Tyne, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Acta Diabetologica
      issn:
         1432-5233
         0940-5429
      volumeNumber:52
Organization:
      name:Springer Milan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:GlaxoSmithKline
      address:
         name:GlaxoSmithKline, Uxbridge, UK
         type:PostalAddress
      name:GlaxoSmithKline
      address:
         name:GlaxoSmithKline, Uxbridge, UK
         type:PostalAddress
      name:Newcastle University
      address:
         name:Newcastle University, Newcastle upon Tyne, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Nigel P. Jones
      affiliation:
            name:GlaxoSmithKline
            address:
               name:GlaxoSmithKline, Uxbridge, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Paula S. Curtis
      affiliation:
            name:GlaxoSmithKline
            address:
               name:GlaxoSmithKline, Uxbridge, UK
               type:PostalAddress
            type:Organization
      name:Philip D. Home
      affiliation:
            name:Newcastle University
            address:
               name:Newcastle University, Newcastle upon Tyne, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:GlaxoSmithKline, Uxbridge, UK
      name:GlaxoSmithKline, Uxbridge, UK
      name:Newcastle University, Newcastle upon Tyne, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(69)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.23s.

LINK . SPRINGER . COM {}